Safety and Efficacy of Achieving Very Low LDL Cholesterol Concentrations with PCSK9 Inhibitors
Machanahalli Balakrishna A, Kaushik S, Tandalam Palanivelu S, Monther N, Ponamgi SP, Alla VM, Patil SM
Journal of clinical medicine · 4 citas
Cómo se estudió
- Diseño
- Metaanálisis (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2025-06-27 · J Clin Med · vol. 14 · número 13 · pág. 4562
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 6 citas · más que el 96% de estudios similares · 5.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 50 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Antiplatelet Therapy and Cardiovascular Diseases · Acute Myocardial Infarction Research
- Palabras clave
- PCSK9 inhibitors, very low LDL cholesterol, LDL cholesterol lowering, major adverse cardiovascular events, drug safety, neurocognitive disorders, diabetes mellitus, muscle disorders, drug discontinuation, cataract, hepatobiliary diseases, cancer risk, intensive lipid-lowering therapy
7 autores
- Akshay Machanahalli Balakrishna🇺🇸 · autor de correspondenciaCreighton University
- Sharanya Kaushik🇺🇸Albert Einstein College of Medicine; Jacobi Medical Center
- Sangeetha Tandalam🇺🇸Creighton University
- Noorhan Monther🇺🇸Creighton University
- Shiva Ponamgi🇺🇸Creighton University
- Venkata Mahesh Alla🇺🇸Creighton University
- Shantanu M. Patil🇺🇸Creighton University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background: The advent of newer pharmacological agents, particularly proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, in combination with conventional lipid-lowering treatments, has allowed for the significant lowering of low-density lipoprotein cholesterol (LDL-C). However, it is unclear if very low LDL-C levels achieved with the use of PCSK-9 inhibitors are associated with increased adverse events that may outweigh potential benefits. Methods: A systematic search of PubMed, Medline, and Cochrane databases was conducted from their inception to 21 February 2025, for randomized controlled trials (RCTs) reporting clinical outcomes with intensive lipid-lowering treatment with PCSK-9 inhibitors leading to very low (Results: A total of six RCTs with 52,951 patients (11,209 very low LDL-C, and 41,742 control) met the inclusion criteria. Compared with patients in the control arm, very low LDL-C was associated with a reduction in MACEs (OR = 0.76, 95% CI: 0.64, 0.89; p 2 = 44.8%). The incidence of most safety outcomes including neurocognitive disorders, diabetes mellitus, muscle disorders, any adverse events, events leading to drug discontinuation, cataract, hepatobiliary disorders, and cancer were comparable between the very low LDL-C and control groups. Conclusions: Very low LDL-C values following intensive lipid-lowering with PCSK-9 inhibitors are associated with a major reduction in cardiovascular events without any significant increase in serious side effects.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.